Embecta

EMBC · NASDAQ

$6.42+$0.0495 (+0.78%)TodayMarket closed · Oct 21, 4:10 AM ET

Prev close $6.37

EMBC analyst rating

HoldConsensus of 3 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold2
Underperform1
Sell0

12-month price target · 5 analysts

Average $10.20 (+58.9% upside)

Low: $3.03
Now: $6.42
High: $23.10

Upgrades and downgrades

The latest rating actions, newest first

EMBC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B of A Securities	May 18, 2026	Maintains	Underperform	$11.00 → $3.00	45%
Mizuho	May 6, 2026	Maintains	Neutral	$12.00 → $5.00	56%
BTIG	May 6, 2026	Downgrade	Buy → Neutral	—	56%
Mizuho	Apr 13, 2026	Maintains	Neutral	$14.00 → $12.00	56%
BTIG	Feb 6, 2026	Maintains	Buy	$25.00	56%

The case for and against

Updated Jul 24, 2026

Bull case

Embecta is facing challenges in its core market, particularly in the U.S., leading to reduced profitability and a revision of its capital allocation priorities. However, its efforts to transition into a broader medical device company and add sales growth may still take shape if the core market stabilizes. The company's revenue and earnings are expected to decline in the near term, with limited visibility for improvement. Despite these challenges, the company has a strong portfolio of products and a leading position in the market, and trades at a discount to its peers.

Bear case

Embecta is a medical device company with a diverse portfolio of products aimed at helping patients with diabetes. Despite its market leadership and global presence, the company has recently faced challenges in the US market, leading to a significant decline in its profitability outlook. This, coupled with the uncertainties surrounding future headwinds and commercial execution, has resulted in a negative outlook for the company's stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.